Nienke W. Boderie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nienke W. Boderie has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Jasper V. Been
Division of Neonatology, Department of Neonatal and Paediatric Intensive Care, Erasmus MC Sophia Children's Hospital University Medical Centre Rotterdam Rotterdam The Netherlands
8 shared publications - Alex Burdorf
Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
3 shared publications Aziz Sheikh
Centre for Medical Informatics, Usher Institute, The University of Edinburgh, Edinburgh, UK
2 shared publicationsFrank J van Lenthe
Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
2 shared publicationsFrank J. van Lenthe
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
2 shared publications- Frank J. van Lenthe
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 21 November 2025
- Published by Elsevier in Public Health
- Vol. 250, 106058
Educational inequalities in smoking-attributable mortality in Europe: Understanding trends between 2000 and 2020
- 21 November 2025
- Published by Elsevier in Public Health
- Vol. 250, 106058
Open AccessEducational inequalities in smoking-attributable mortality in Europe: Understanding trends between 2000 and 2020
- Open Access
- 6 August 2025
- Published by Taylor & Francis in Critical Public Health
- Vol. 35 (1)
PERSonalised incentives for supporting tobacco cessation (PERSIST) among healthcare employees: evaluation and lessons learned
- 6 August 2025
- Published by Taylor & Francis in Critical Public Health
- Vol. 35 (1)
Open AccessPERSonalised incentives for supporting tobacco cessation (PERSIST) among healthcare employees: evaluation and lessons learned
- Open Access
- 18 September 2024
- Published by Elsevier in Public Health
- Vol. 236, 322-327
Impact of COVID-19 mitigation measures on perinatal outcomes in the Netherlands
- 18 September 2024
- Published by Elsevier in Public Health
- Vol. 236, 322-327
Open AccessImpact of COVID-19 mitigation measures on perinatal outcomes in the Netherlands
- Open Access
- 17 January 2024
- Published by European Publishing in Tobacco Induced Diseases
- Vol. 22 (January) , 1-9
Public support for smoke-free private indoor and public outdoor areas in the Netherlands: A trend analysis from 2018– 2022
Introduction: In addition to smoke-free policies in indoor public and workplaces, governments increasingly implement smoke-free policies at beaches, in parks, playgrounds and private cars (‘novel smoke-free policies’). An important element in the implementation of such policies is public...
- 17 January 2024
- Published by European Publishing in Tobacco Induced Diseases
- Vol. 22 (January) , 1-9
Open AccessPublic support for smoke-free private indoor and public outdoor areas in the Netherlands: A trend analysis from 2018– 2022
Introduction: In addition to smoke-free policies in indoor public and workplaces, governments increasingly implement smoke-free policies at beaches, in parks, playgrounds and private cars (‘novel smoke-free policies’). An important element in the implementation of such policies is public...
- Open Access
- 9 May 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 59, 101982
Public support for smoke-free policies in outdoor areas and (semi-)private places: a systematic review and meta-analysis
- 9 May 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 59, 101982
Open AccessPublic support for smoke-free policies in outdoor areas and (semi-)private places: a systematic review and meta-analysis
- Open Access
- 18 February 2022
- Published by European Publishing in Tobacco Prevention & Cessation
- Vol. 8 (February) , 1-6
Pediatric patients’ views regarding smoke-free hospital grounds compared to those of adults: A survey study
Introduction: Children are important stakeholders in discussions about regulation of smoking and protection from secondhand smoke, but are rarely acknowledged as such. We explored the opinion of pediatric patients and other key stakeholders regarding the planned smoke-free zone around the...
- 18 February 2022
- Published by European Publishing in Tobacco Prevention & Cessation
- Vol. 8 (February) , 1-6
Open AccessPediatric patients’ views regarding smoke-free hospital grounds compared to those of adults: A survey study
Introduction: Children are important stakeholders in discussions about regulation of smoking and protection from secondhand smoke, but are rarely acknowledged as such. We explored the opinion of pediatric patients and other key stakeholders regarding the planned smoke-free zone around the...
- Open Access
Assessing public support for extending smoke-free policies beyond enclosed public places and workplaces: protocol for a systematic review and meta-analysis
Introduction Smoke-free enclosed public environments are effective in reducing exposure to secondhand smoke and yield major public health benefits. Building on this, many countries are now implementing smoke-free policies regulating smoking beyond enclosed public places and workplaces. In order to successfully implement such ‘novel smoke-free policies’, public support is essential. We aim to provide the first comprehensive systematic review and meta-analysis assessing levels and determinants of public support for novel smoke-free policies. Methods and analysis The primary objective of this review is to summarise the level of public support for novel smoke-free policies. Eight online databases (Embase.com, Medline ALL Ovid, Web of Science Core Collection, WHO Library Database, Latin American and Caribbean Health Sciences Literature, Scientific Online Library Online, PsychINFO and Google Scholar) will be searched from 1 January 2004 by two independent researchers with no language restrictions. The initial search was performed on 15 April 2020 and will be updated prior to finalisation of the report. Studies are eligible if assessing support for novel smoke-free policies in the general population (age ≥16 years) and have a sample size of n≥400. Studies funded by the tobacco industry or evaluating support among groups with vested interest are excluded. The primary outcome is proportion of public support for smoke-free policies, subdivided according to the spaces covered: (1) indoor private spaces (eg, cars) (2) indoor semiprivate spaces (eg, multi-unit housing) (3) outdoor (semi)private spaces (eg, courtyards) (4) non-hospitality outdoor public spaces (eg, parks, hospital grounds, playgrounds) and (5) hospitality outdoor public spaces (eg, restaurant terraces). The secondary objective is to identify determinants associated with public support on three levels: (1) within-study determinants (eg, smoking status) (2) between-study determinants (eg, survey year) and (3) context-specific determinants (eg, social norms). Risk of bias will be assessed using the Mixed Methods Appraisal Tool and a sensitivity analysis will be performed excluding studies at high risk of bias. Ethics and dissemination No formal ethical approval is required. Findings will be disseminated to academics, policymakers and the general public.
Open AccessAssessing public support for extending smoke-free policies beyond enclosed public places and workplaces: protocol for a systematic review and meta-analysis
Introduction Smoke-free enclosed public environments are effective in reducing exposure to secondhand smoke and yield major public health benefits. Building on this, many countries are now implementing smoke-free policies regulating smoking beyond enclosed public places and workplaces. In order to successfully implement such ‘novel smoke-free policies’, public support is essential. We aim to provide the first comprehensive systematic review and meta-analysis assessing levels and determinants of public support for novel smoke-free policies. Methods and analysis The primary objective of this review is to summarise the level of public support for novel smoke-free policies. Eight online databases (Embase.com, Medline ALL Ovid, Web of Science Core Collection, WHO Library Database, Latin American and Caribbean Health Sciences Literature, Scientific Online Library Online, PsychINFO and Google Scholar) will be searched from 1 January 2004 by two independent researchers with no language restrictions. The initial search was performed on 15 April 2020 and will be updated prior to finalisation of the report. Studies are eligible if assessing support for novel smoke-free policies in the general population (age ≥16 years) and have a sample size of n≥400. Studies funded by the tobacco industry or evaluating support among groups with vested interest are excluded. The primary outcome is proportion of public support for smoke-free policies, subdivided according to the spaces covered: (1) indoor private spaces (eg, cars) (2) indoor semiprivate spaces (eg, multi-unit housing) (3) outdoor (semi)private spaces (eg, courtyards) (4) non-hospitality outdoor public spaces (eg, parks, hospital grounds, playgrounds) and (5) hospitality outdoor public spaces (eg, restaurant terraces). The secondary objective is to identify determinants associated with public support on three levels: (1) within-study determinants (eg, smoking status) (2) between-study determinants (eg, survey year) and (3) context-specific determinants (eg, social norms). Risk of bias will be assessed using the Mixed Methods Appraisal Tool and a sensitivity analysis will be performed excluding studies at high risk of bias. Ethics and dissemination No formal ethical approval is required. Findings will be disseminated to academics, policymakers and the general public.
- Open Access
PERSonalised Incentives for Supporting Tobacco cessation (PERSIST) among healthcare employees: a randomised controlled trial protocol
Background Smoking is the primary preventable risk factor for disease and premature mortality. It is highly addictive and cessation attempts are often unsuccessful. Incentive-based programmes may be an effective method to reach sustained abstinence. Individualisation of incentives based on personal characteristics yields potential to further increase the effectiveness of incentive-based programmes. Method A randomised controlled trial among healthcare workers recruited through their employer and signed up for a group-based smoking cessation programme. The intervention under study is the provision of personalised incentives on validated smoking cessation at several time points after the smoking cessation programme. A total of 220 participants are required. Participants are randomised 1:1 into intervention (personalised incentives) or control (no incentives). All participants join the group-based programme. Incentives are provided on validated abstinence directly after the smoking cessation programme and after 3, 6 and 12 months. Incentives are provided according to four schemes: (1) Standard: total reward size €350, pay-out scheme: €50 (t=0), €50 (t=3 months), €50 (t=6 months) and €200 (t=12 months), (2) descending: total reward size €300, pay-out scheme: €150, €100, €50 and €0, (3) ascending: total reward size: €400, pay-out scheme: €0, €0, €50 and €350 and (4) deposit: total reward size €450, pay-out scheme: €50, €50, €150, €200; participants pay a €100 deposit, returned conditional on abstinence after 6 months. Advice on which incentive scheme suits participants best is based on willingness to provide a deposit, readiness to quit, nicotine dependency and long-term or short-term reward preference. Participants are free to deviate from this advice. Abstinence is validated at each time point, with 15 months of total follow-up. The primary end point is validated abstinence at 12 months. Effectiveness will be determined by intention-to-treat analysis. Ethics and dissemination The Erasmus MC Medical Ethics Committee decided that according to the Dutch Human Research Law (WMO), the protocol required no formal ethical approval. The results will be published in a peer-reviewed scientific journal and communicated to the participants. Trial registration number Netherlands Trial Register NL7711.
Open AccessPERSonalised Incentives for Supporting Tobacco cessation (PERSIST) among healthcare employees: a randomised controlled trial protocol
Background Smoking is the primary preventable risk factor for disease and premature mortality. It is highly addictive and cessation attempts are often unsuccessful. Incentive-based programmes may be an effective method to reach sustained abstinence. Individualisation of incentives based on personal characteristics yields potential to further increase the effectiveness of incentive-based programmes. Method A randomised controlled trial among healthcare workers recruited through their employer and signed up for a group-based smoking cessation programme. The intervention under study is the provision of personalised incentives on validated smoking cessation at several time points after the smoking cessation programme. A total of 220 participants are required. Participants are randomised 1:1 into intervention (personalised incentives) or control (no incentives). All participants join the group-based programme. Incentives are provided on validated abstinence directly after the smoking cessation programme and after 3, 6 and 12 months. Incentives are provided according to four schemes: (1) Standard: total reward size €350, pay-out scheme: €50 (t=0), €50 (t=3 months), €50 (t=6 months) and €200 (t=12 months), (2) descending: total reward size €300, pay-out scheme: €150, €100, €50 and €0, (3) ascending: total reward size: €400, pay-out scheme: €0, €0, €50 and €350 and (4) deposit: total reward size €450, pay-out scheme: €50, €50, €150, €200; participants pay a €100 deposit, returned conditional on abstinence after 6 months. Advice on which incentive scheme suits participants best is based on willingness to provide a deposit, readiness to quit, nicotine dependency and long-term or short-term reward preference. Participants are free to deviate from this advice. Abstinence is validated at each time point, with 15 months of total follow-up. The primary end point is validated abstinence at 12 months. Effectiveness will be determined by intention-to-treat analysis. Ethics and dissemination The Erasmus MC Medical Ethics Committee decided that according to the Dutch Human Research Law (WMO), the protocol required no formal ethical approval. The results will be published in a peer-reviewed scientific journal and communicated to the participants. Trial registration number Netherlands Trial Register NL7711.